Biotechnology company providing psychedelic-therapies through technology-focused, data driven and medical based solutions for addictions and mental health patients Mycotopia Therapies Inc. (OTCMKTS: TPIA) is seeking to enter the $13 billion medicinal mushroom market with HAVN Life Sciences Inc. (CSE: HAVN) (OTCMKTS: HAVLF) biopharmaceuticals and Ei. Ventures MANA products.
Before acquiring Ei. Ventures, Mycotopia is planning to first form PSLY.COM, the company has also expanded its supply agreement with HAVN Life Sciences to include functional mushroom. Not long ago, HAVN Life Sciences launched natural health products and its line of white label products.
Recently acquired 12x 12 estate in The Sandbox- a virtual world where players can build, own, and monetize their gaming experiences on the Ethereum blockchain will also be using the name PSY.COM.
The Sandbox was bought for $2.2 million and it represents the third largest land scale in the metaverse.
Citing the existing agreement, HAVN Life Sciences supplied Mycotopia with naturally-extracted psilocybin compounds for use by United States based researchers, universities and companies.
With the expanded agreement, HAVN Life will supply Mycotopia with its functional mushrooms as well as the white label supply and distribution of HAVN’s line of natural OTC health products which are currently registered with the Jamaican Ministry of Health.
“We are delighted to grow our partnership with Mycotopia through the expansion of our supply agreement. We welcome the opportunity to see our products reach a broader market and look forward to working with Ben and his team in their development of plant-derived, therapeutic treatment options that address global mental healthcare needs,” said the CEO of HAVN Life, Tim Moore.
